Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Brolucizumab 6 mg Prefilled Syringe in nAMD
NCT03930641Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started May 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03930641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930641.